BiovitalsHF™, a Prescription Software Uses Data Science to Augment Guideline-directed Use of Heart Failure Therapies

BOSTON, March 13, 2019 /PRNewswire/ -- Biofourmis, a fast-growing digital therapeutics company focused on augmenting personalized care and therapies to empower patients with complex chronic conditions, today joined the American Heart Association's Center for Health Technology & Innovation's (Center) Innovators Network to deliver personalized software-based intervention including dose changes, heart failure education and insights to patients with heart failure.

The Association's Center for Health Technology & Innovation is focused on building and fostering health technologies and relationships in pursuit of innovative and scalable solutions across the healthcare market. The Center helps members of its Innovators Network in the healthcare technology field align and integrate their technology with Association's digital resources to encourage development and adoption of digital healthcare solutions.

Biofourmis' BiovitalsHF™ platform utilizes software (along with wearable biosensors, and adjunctive pharmacotherapy) to manage patients suffering from heart failure. Once activated, a treatment algorithm dynamically prescribes optimal guideline-directed HF therapies, guides adherence and overall behavior progress. Biofourmis' approach to managing patients with heart failure coupled with the health education content and care pathways from the American Heart Association portfolio (called, CarePlans) will make managing heart failure and associated co-morbidities easier for patients.

"More than 50% of the whole world lives with chronic diseases leading to a global economic burden of 47 trillion dollars. In the U.S., less than 1% of the heart failure patients are on optimal heart failure dosage of medication¹ leading to one in four patients being re-hospitalized within 30-days of discharge²," said Kuldeep Singh Rajput, Founder & CEO of Biofourmis. Our prescription software app aims at changing the behavior at the root cause of disease using the Association's science-based guideline-directed therapies, CarePlans and health content with the intent of educating and engaging at scale with the promise of improving health outcomes"

Biofourmis, now a member of American Heart Association's Center for Health Technology Innovators Network, empowers people with heart failure, with information and insights that they can act on to improve their condition. Their proprietary analytics platform Biovitals™ is an AI-empowered health analytics engine that continuously personalizes user experience to optimize engagement and predicts clinical exacerbation days in advance before a critical event. Biofourmis' data science team has combined guideline-directed therapeutic titration algorithms with health content to improve patient-centric outcomes.

Biofourmis' therapeutic platform is based on emerging clinical evidence that drug-software combinations can enhance clinical effectiveness, including patient reported outcomes. It has the potential of getting the right patients on the right drugs at the right dosage in a timely manner," said Dr. Maulik Majmudar, a cardiologist and member of Biofourmis' Clinical Advisory Board. "Leveraging Biofourmis' platform to support people with complex chronic conditions at scale is an important step in making a meaningful impact on people's quality of life."

1. Medical Therapy for Heart Failure With Reduced Ejection Fraction, doi: [10.1016/j.jacc.2018.04.070]
2. Krumholz HM, Merrill AR, Schone EM, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes. 2009;2(5):407-413.

About Biofourmis

Biofourmis is a fast-growing global start-up that is on a mission of augmenting personalized care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. They discover, develop and deliver clinically-validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, and cost-effective solutions for payers. Biofourmis has built Biovitals™, a highly sophisticated personalized AI-empowered health analytics platform that predicts clinical exacerbation days in advance before a critical event, which is the backbone of their Digital Therapeutics product pipeline across therapeutic areas including heart failure, acute coronary syndrome, COPD, and chronic pain. For more information visit: www.biofourmis.com

INQUIRIES:

Tien Ma
[email protected] 
+49-1638358774

SOURCE Biofourmis